Screening of blood donors for hepatitis C virus RNA with the MagNA Pure-COBAS AmpliScreen method

Transfusion

Volumn 45, Issue 9, 2005, Pages 1518-1522

  Palomäki, Pekka ^a   Wessberg, Susanna ^a   Tuomi, Katri ^a   Laitinen, Harri ^a  

^a FINNISH RED CROSS BLOOD SERVICE   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS RNA;

ARTICLE; BLOOD DONOR; BLOOD TRANSFUSION; CONTROLLED STUDY; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; HUMAN TISSUE; NUCLEIC ACID AMPLIFICATION; SCREENING; VIRAL CONTAMINATION; VIRUS TRANSMISSION; BLOOD; BLOOD BANK; EVALUATION; GENETICS; GENOTYPE; HEPATITIS C; ISOLATION AND PURIFICATION; MASS SCREENING; METHODOLOGY; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; STANDARD;

BLOOD BANKS; BLOOD DONORS; EVALUATION STUDIES; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMANS; MASS SCREENING; NUCLEIC ACID AMPLIFICATION TECHNIQUES; REPRODUCIBILITY OF RESULTS; RNA, VIRAL; SENSITIVITY AND SPECIFICITY;

EID: 26944453239     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2005.00557.x     Document Type: Article

References (14)

1. Engelfriet CP. International forum: implementation of donor screening for infectious agents transmitted by blood by nucleic acid technology. Vox Sang 2002;82:87-111.
2. Cuypers HT, van Dijk R, Viret JF, et al. European multicentre validation study of NuliSens Extractor in combination with HCV Amplicor 2.0 for HCV-NAT screening of plasmapools. Biologicals 1999;27:303-14.
3. Saldanha J, Lelie N, Heat A. Establishment of the first international standard for nucleic acid amplification technology (NAT) assays for HCV RNA. WHO Collaborative Study Group. Vox Sang 1999;76:149-58.
4. Finnley DJ. Probit analysis: parallel line analysis. 3rd ed. Cambridge: Cambridge University Press; 1971.
5. Kessler HH, Clarici AMK, Stelzl E, et al. Fully automated detection of hepatitis C virus RNA in serum and whole blood samples. Clin Diagn Lab Immunol 2002;9:1385-8.
6. Germer JJ, Lins MM, Jensen ME, et al. Evaluation of the MagNA Pure LC instrument for extraction of hepatitis C virus RNA for the COBAS Amplicor Hepatitis C Virus Test, version 2.0. J Clin Microbiol 2003;41:3503-8.
7. Cook L, Ng KW, Bagabag A, et al. Use of the MagNA Pure LC automated nucleic acid extraction system followed by real-time reverse transcription-PCR for ultrasensitive quntitation of hepatitis C virus RNA. J Clin Microbiol 2004;42:4130-6.
8. Hölzl G, Stöcher M, Leb V, et al. Entirely automated quantification of human immunodeficiency virus type 1 (HIV-1) RNA in plasma by using the ultrasensitive Cobas Amplicor HIV-1 Monitor test and RNA purification on the MagNA Pure LC instrument. J Clin Microbiol 2003;41:1248-51.
9. Lee BG, Fiebelkorn KR, Caliendo AM, et al. Development and verification of an automated sample processing protocol for quantification of human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol 2003;41:2062-7.
10. Leb V, Stöcher M, Valentine-Thon E, et al. Fully automated, internally controlled quantification of hepatitis B virus DNA by real-time PCR by use of the MagNA Pure LC and LightCycler instruments. J Clin Microbiol 2004;42: 585-90.
11. CPMP: the introduction of nucleic acid amplification technology (NAT) for the detection of hepatitis C virus RNA in plasma pools. CPMP/BWP/390/97. London: EMEA; 1998.
12. Council of Europe. Guide to the preparation, use and quality assurance of blood components. Recommendation R (95) 15, 10th ed. Strasbourg Cedex: Council of Europe Publishing; 2004.
13. Velati C, Laperche S, Hossenlopp C, Rouger P. NAT screening in Europe [abstract]. Vox Sang 2004;87:26.
14. Müller-Breitkreutz K. Results of viral marker screening of unpaid blood donations and probability of window period donations in 1997. Vox Sang 2000;78:149-57.